STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #744 by analyst upside · 2026-06-27
VIR
Vir Biotechnology, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+114.9%
implied upside to consensus target
Current Price $10.03
Consensus Target $21.56
Bull Target $30.0
Bear Target $16.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
0
Sell
0
52-Week Low $4.16
52-Week High $11.66
YTD Return +68.9%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -4.3x
EPS (TTM) $-3.13
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $65M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.16
52-Week High $11.66
Current Price $10.03
Bear Target $16.0
Bull Target $30.0
● Now $10.03 ● Target $21.56
TRADING DATA
Avg Volume 1.8M
YTD Return +68.9%
Analyst Count 9
Consensus Buy
Upside to Target +114.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Vir Biotechnology, Inc. (VIR) is currently trading at $10.03 with a Wall Street consensus price target of $21.56, implying potential upside of 114.9% over the next 12 months. 9 analysts currently cover VIR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $16.0.

VIR operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 68.9% year-to-date and is currently trading near the upper end of its 52-week range of $4.16 – $11.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VIR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley — Reiterated
Overweight → Overweight 2026-06-11 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-06-03 29% win rate (7 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-04 31% win rate (48 calls)
Barclays — Reiterated
Overweight → Overweight 2026-02-25 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-02-24 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-02-24 Building track record
Needham — Reiterated
Buy → Buy 2026-02-24 20% win rate (5 calls)
Needham reit
Buy → Buy 2026-02-09 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
18/30
Consensus clarity
2/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →